WTAP/YTHDC1-mediated m6A modification of P4HA1 suppresses hepatic gluconeogenesis and ameliorates MASLD by activating AKT signaling.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global metabolic epidemic with limited therapeutic options. Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) has been implicated in glucose metabolism, but its functional role and regulatory mechanisms in MASLD remain unknown. In this study, we establish...